

KORSUVA[®] is the First and Only FDA-approved Treatment Indicated for Moderate-to-Severe CKD-αP in Adults Undergoing Hemodialysis¹

Unique KORSUVA[®] HCPCS Code

J0879

Injection, difelikefalin, 0.1 microgram (for ESRD on dialysis)

The information contained within this resource is provided for informational purposes only. Healthcare providers should make the ultimate determination as to when to use a specific product based on clinical appropriateness for a particular patient.

HCPCS Code²

HCPCS Code	J0879
HCPCS Description	Difelikefalin, 0.1 microgram (for ESRD on dialysis)
JZ Modifier	Zero drug amount discarded/not administered to any patient
JW Modifier	Drug amount discarded/not administered to any patient

CPT Codes^{3,4}

Intravenous (IV) administration

96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); IV push, single or initial substance/drug
96375	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential IV push of a new substance/drug (list separately in addition to code for primary procedure)

National Drug Codes (NDCs)^{1*}

59353-0065-01	KORSUVA [®] injection 65 mcg/1.3 (50 mcg/mL) single-dose vial
59353-0065-12	Carton containing 12 vials

* Note that the product's NDC code has been "zero-filled" to ensure creation of an 11-digit code that meets HIPAA standards. The zero-fill location is indicated in bold. Payer requirements regarding use of a 10-digit or 11-digit NDC may vary.

Diagnosis: ICD-10-CM Codes⁵

L29.8	Other pruritus
L29.9	Pruritus, unspecified

Revenue Code⁶

0636	Drugs requiring detailed coding
------	---------------------------------

INDICATION

KORSUVA[®] is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-αP) in adults undergoing hemodialysis (HD).

Limitation of Use: KORSUVA[®] has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances: These adverse reactions, including falls, have occurred in patients taking KORSUVA[®] and may subside with continued treatment. The incidence of somnolence was higher in KORSUVA[®]-treated subjects 65 years of age and older (7.0%) than in KORSUVA[®]-treated subjects less than 65 years of age (2.8%). Concomitant use of centrally acting depressant medications, sedating antihistamines, and opioid analgesics may increase the likelihood of these adverse reactions and should be used with caution during treatment with KORSUVA[®].

CKD-αP=chronic kidney disease-associated pruritus; CPT=Current Procedural Terminology; ESRD=end-stage renal disease; FDA=U.S. Food and Drug Administration; HCPCS=Healthcare Common Procedure Coding System; HIPAA=Health Insurance Portability and Accountability Act; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

KORSUVA® is available in the US through the following specialty distributors:

ASD Healthcare

☎ 800 746-6273

Ordering: ✉ dialysis@asdhealthcare.com

Cardinal Health™ Metro Medical™ Distribution

☎ 800 768-2002

Account set up: ✉ customersvc@cardinalhealth.com

Ordering: 🌐 www.metromedicalorder.com

Cardinal Health™ Specialty Pharmaceutical Distribution

☎ 855 855-0708 (hospitals)

☎ 866 677-4844 (specialty & retail pharmacy)

Ordering: ✉ GMB-spd-csorderentry@cardinalhealth.com

🌐 www.cardinalhealth.com/en/solutions/specialty-distribution-services.html

KORSUVA® (difelikefalin) Injection

65 mcg/1.3 mL (50 mcg/mL)

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Risk of Driving and Operating Machinery:

Dizziness, somnolence, and mental status changes have occurred in patients taking KORSUVA®. KORSUVA® may impair mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of KORSUVA® on their ability to do so is known.

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 2\%$ and $\geq 1\%$ higher than placebo) were diarrhea (9.0%), dizziness (6.8%), nausea (6.6%), gait disturbances, including falls (6.6%), hyperkalemia (4.7%), headache (4.5%), somnolence (4.2%), and mental status changes (3.3%).

USE IN SPECIFIC POPULATIONS

Severe Hepatic Impairment: The influence of severe hepatic impairment on the pharmacokinetics of KORSUVA® in subjects undergoing hemodialysis (HD) has not been evaluated; therefore, use of KORSUVA® in this population is not recommended.

Geriatric Use: The incidence of somnolence was higher in KORSUVA®-treated subjects aged 65 years and older (7.0%) than in KORSUVA®-treated subjects less than 65 years of age (2.8%). The incidence was comparable in both placebo age groups (3.0% and 2.1%, respectively) (see Warnings and Precautions).

Please see accompanying full [Prescribing Information](#).

References:

1. KORSUVA® (difelikefalin) [Prescribing Information]. St. Gallen, Switzerland: Vifor (International) Inc. Revised April 2024.
2. Centers for Medicare and Medicaid Services. Transmittal R11278CP. <https://www.cms.gov/files/document/r11278cp.pdf>. Accessed September 9, 2025.
3. American Academy of Professional Coders. CPT 96374. <https://www.aapc.com/codes/cpt-codes/96374>. Accessed September 9, 2025.
4. American Academy of Professional Coders. CPT 96375. <https://www.aapc.com/codes/cpt-codes/96375>. Accessed September 9, 2025.
5. Centers for Medicare and Medicaid Services. ICD-10-CM tabular list of disease and injuries. <https://www.cms.gov/files/zip/2022-code-tables-tabular-and-index-updated-02012022.zip>. Accessed September 9, 2025.
6. Noridian Medicare. Revenue codes. <https://med.noridianmedicare.com/web/jfa/topics/claim-submission/revenue-codes>. Accessed September 9, 2025.